Skip to Content

Brinavess Approval Status

  • FDA approved: No
  • Brand name: Brinavess
  • Generic name: vernakalant
  • Dosage form: Intravenous Injection
  • Previous name: Kynapid
  • Company: Cardiome Pharma Corp.
  • Treatment for: Atrial Fibrillation

Brinavess (vernakalant) is an investigational antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.

Development Status and FDA Approval Process for Brinavess

Aug 21, 2017Cardiome Provides U.S. Regulatory Update for Brinavess
Aug 12, 2009Additional Clinical Trial to be Conducted for Kynapid Under FDA Special Protocol Agreement
Oct  9, 2008Cardiome Provides Kynapid Regulatory Update
Aug 11, 2008Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For Kynapid
Jan 22, 2008Cardiome And Astellas Announce Kynapid Regulatory Update
Dec 12, 2007FDA Advisory Committee Recommends Approval of Kynapid for Acute Atrial Fibrillation
Aug 30, 2007Cardiome And Astellas Announce Regulatory Extension
Feb 19, 2007Cardiome And Astellas Announce Acceptance Of NDA For Review
Dec 18, 2006Cardiome and Astellas Pharma US, Inc. Announce Re-Submission of NDA for Vernakalant (IV)
May 31, 2006Cardiome Announces Refusal to File Decision By the FDA
Mar 31, 2006New Drug Application Submitted For RSD1235

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.